<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS97964</article-id>
<article-id pub-id-type="doi">10.1101/2020.09.18.304493</article-id>
<article-id pub-id-type="archive">PPR215183</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An immunodominance hierarchy exists in CD8<sup>+</sup> T cell responses to HLA-A*02:01-restricted epitopes identified from the non-structural polyprotein 1a of SARS-CoV-2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Takagi</surname>
<given-names>Akira</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matsui</surname>
<given-names>Masanori</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>School of Medical Technology, Faculty of Health and Medical Care, Saitama Medical University, 1397-1 Yamane, Hidaka-city, Saitama 350-1241, Japan</aff>
<aff id="A2">
<label>2</label>Department of Microbiology, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding author. <email>mmatsui@saitama-med.ac.jp</email>, Tel: +81-49-276-1438; Fax: +81-49-295-9107.</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>19</day>
<month>09</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">COVID-19 vaccines are being rapidly developed and human trials are underway. Almost all of these vaccines have been designed to induce antibodies targeting spike protein of SARS-CoV-2 in expectation of neutralizing activities. However, non-neutralizing antibodies are at risk of causing antibody-dependent enhancement. Further, the longevity of SARS-CoV-2-specific antibodies is very short. Therefore, in addition to antibody-induced vaccines, novel vaccines on the basis of SARS-CoV-2-specific cytotoxic T lymphocytes (CTLs) should be considered in the vaccine development. Here, we attempted to identify HLA-A*02:01-restricted CTL epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2. Eighty-two peptides were firstly predicted as epitope candidates on bioinformatics. Fifty-four in 82 peptides showed high or medium binding affinities to HLA-A*02:01. HLA-A*02:01 transgenic mice were then immunized with each of the 54 peptides encapsulated into liposomes. The intracellular cytokine staining assay revealed that 18 out of 54 peptides were CTL epitopes because of the induction of IFN-γ-producing CD8<sup>+</sup> T cells. In the 18 peptides, 10 peptides were chosen for the following analyses because of their high responses. To identify dominant CTL epitopes, mice were immunized with liposomes containing the mixture of the 10 peptides. Some peptides were shown to be statistically predominant over the other peptides. Surprisingly, all mice immunized with the liposomal 10 peptide mixture did not show the same reaction pattern to the 10 peptides. There were three pattern types that varied sequentially, suggesting the existence of an immunodominance hierarchy, which may provide us more variations in the epitope selection for designing CTL-based COVID-19 vaccines.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>COVID-19</kwd>
<kwd>CTL epitope</kwd>
<kwd>HLA-A*02:01</kwd>
<kwd>pp1a</kwd>
<kwd>vaccine</kwd>
<kwd>immunodominance</kwd>
<kwd>hierarchy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">In December 2019, the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly identified in Wuhan, Hubei province, China. Since then, its subsequent spread of global infection has still continued to gain momentum. As of September 16th, 2020, the COVID-19 pandemic has infected more than 29.4 million people around the world and caused more than 931,000 deaths. Although the clinical symptom is varied from asymptomatic or mild self-limited infection to severe life-threating respiratory disease, the mechanism of disease outcome remains unclear. Many nations are struggling to find appropriate preventive and control strategies. However, there are no vaccines or antiviral drugs available for the treatment of this infectious disease.</p>
<p id="P3">There are seven coronaviruses that infect humans. In addition to SARS-CoV-2, SARS-CoV and middle-east respiratory syndrome coronavirus (MERS-CoV) cause severe pneumonia, whereas the other four human coronaviruses including HCoV-229E, -NL63, -OC43 and -HKU1 cause common cold (<xref ref-type="bibr" rid="R1">1</xref>). Like other coronaviruses, SARS-CoV-2 possesses a large single-stranded positive sense RNA genome (<xref ref-type="bibr" rid="R2">2</xref>). As shown in <xref ref-type="fig" rid="F1">Fig. 1</xref>, the 5’-terminal two-thirds of the genome are composed of ORF1a and ORF1b. ORF1a encodes the polyprotein 1a (pp1a) containing non-structural proteins (nsp1-11) (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The remaining one-third of the genome encodes the structural proteins involving spike (S), envelope (E), membrane (M), and nucleocapsid (N) as well as accessory proteins (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Coronaviruses depend on S protein for binding to host cells. The host cell receptor for SARS-CoV-2 is the angiotensin-converting enzyme 2 (ACE2) which is also the receptor for SARS-CoV (<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R4">4</xref>).</p>
<p id="P4">It was shown that the increased cell numbers of antibody-secreting cells, follicular helper T cells, activated CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells were observed in a non-severe COVID-19 patient (<xref ref-type="bibr" rid="R5">5</xref>), indicating that robust immune responses can be elicited to the newly emerged, SARS-CoV-2. Therefore, the induction of protective immunity against SARS-CoV-2 is considered to help control COVID-19. Vaccines are being rapidly developed in the world, and human trials are underway for several vaccine candidates, ranging from traditional vaccines comprised of inactivated SARS-CoV-2 preparations (<xref ref-type="bibr" rid="R6">6</xref>) to innovative vaccines such as subunit (<xref ref-type="bibr" rid="R7">7</xref>), RNA (<xref ref-type="bibr" rid="R8">8</xref>), DNA (<xref ref-type="bibr" rid="R9">9</xref>), and adenoviral (<xref ref-type="bibr" rid="R10">10</xref>) vaccines. Almost all of these vaccines have been designed to induce antibodies targeting S protein because some antibodies specific for the receptor binding domain (RBD) of S protein may have neutralizing activities and can interfere with the binding between ACE2 on host cells and virus. In fact, it was reported that DNA vaccine encoding S protein induced neutralizing antibody in rhesus macaques and protected them from the challenge with SARS-CoV-2 (<xref ref-type="bibr" rid="R9">9</xref>). However, there are two major issues concerning this vaccine. One issue is that non-neutralizing and sub-neutralizing antibodies to S protein induced by this vaccine are at risk of causing antibody-dependent enhancement (ADE) (<xref ref-type="bibr" rid="R11">11</xref>). ADE is the phenomenon in which binding of suboptimal antibodies to viruses enhances viral entry mediated by Fc receptors into immune cells, and promotes inflammatory and tissue injury (<xref ref-type="bibr" rid="R12">12</xref>). ADE has been reported in the evaluation of vaccine candidates directed to S protein for SARS-CoV (<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R16">16</xref>). Because of their similarities, these findings enable us to foresee the high risks of ADE in SARS-CoV-2 vaccines directed to S protein. It is worth noting that RBD-specific antibodies with potent neutralizing activity are extremely rare among S-specific antibodies in COVID-19-covalescent individuals (<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref>), suggesting that the development of effective vaccines might requires novel strategies to selectively target RBD of SARS-CoV-2. On the other hand, Passive immunization of RBD-specific monoclonal antibodies obtained from convalescent individuals might be safe and effective for the elimination of SARS-CoV-2 (<xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R21">21</xref>), but much more expensive to produce for worldwide use than vaccines (<xref ref-type="bibr" rid="R22">22</xref>). The other issue is the short longevity of neutralizing antibodies to SARS-CoV-2. It was previously reported that the SARS-CoV-specific antibodies are short-lived for at most about 2-3 years (<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R24">24</xref>) in comparison with SARS-CoV-specific memory T cells (<xref ref-type="bibr" rid="R25">25</xref>). The longevity of SARS-CoV-2-specific antibodies are likely to be even shorter, as indicated by antibody titers being undetectable or approaching baseline in the majority of SARS-CoV-2-infected individuals after 2-3 months post onset of symptoms (<xref ref-type="bibr" rid="R26">26</xref>). Taken together, these data strongly suggest that it does not seem right to rely too much on just the S-specific antibody-induced vaccine to control the COVID-19 pandemic.</p>
<p id="P5">In the viral infection, CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) play an important role for the clearance of virus as well as neutralizing antibodies. CTLs recognize virus-derived peptides in association with major histocompatibility complex class I (MHC-I) molecules on the surface of antigen presenting cells and kill virus-infected target cells. It was reported that CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells are decreased in proportion to the disease severity and are exhausted in severe COVID-19 patients (<xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R28">28</xref>), suggesting the significance of CD8<sup>+</sup> CTLs in the clearance of SARS-CoV-2. Furthermore, SARS-CoV-specific memory T cells persisted up to 11 years (<xref ref-type="bibr" rid="R25">25</xref>), predicting the long life of SARS-CoV-2-specific memory T cells. Therefore, in addition to antibody-induced vaccines, novel vaccines based on SARS-CoV-2-specific CTLs should also be considered in the future vaccine development for the prevention and disease control of COVID-19.</p>
<p id="P6">For the development of CTL-based COVID-19 vaccine, we here attempted to identify HLA-A*02:01-restricted, dominant CTL epitopes derived from pp1a of SARS-CoV-2. Pp1a is a largest protein composed of 4,401 amino acids among SARS-CoV-2 proteins, and therefore, it seems highly possible to find dominant epitopes in this protein. Furthermore, pp1a is produced first in SARS-CoV-2-infected cells, suggesting pp1a-specific CTLs could kill infected cells before the formation of mature virions. In addition, this protein is composed of 11 non-structural regulatory proteins that are highly conserved among many different coronaviruses (<xref ref-type="bibr" rid="R29">29</xref>). To identify CTL epitopes, we used computational algorithms, HLA-A*02:01 transgenic mice and the peptide-encapsulated liposomes. In a similar way, we previously identified CTL epitopes of SARS-CoV pp1a (<xref ref-type="bibr" rid="R30">30</xref>).</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<sec id="S3">
<title>Prediction of HLA-A*02:01-restricted CTL epitopes derived from SARS-CoV-2 pp1a</title>
<p id="P7">We firstly attempted to predict HLA-A*02:01-restricted CTL epitopes derived from SARS-CoV-2 pp1a using four computer-based programs, SYFPEITHI (<xref ref-type="bibr" rid="R31">31</xref>), nHLAPred (<xref ref-type="bibr" rid="R32">32</xref>), ProPred-I (<xref ref-type="bibr" rid="R33">33</xref>), and IEDB (<xref ref-type="bibr" rid="R34">34</xref>). Eighty-two epitopes with high scores for all four programs were selected and synthesized into 9-mer peptides (<xref ref-type="table" rid="T1">Table 1</xref>). These peptides were then evaluated for their binding affinities to HLA-A*02:01 molecule using TAP2-deficient RMA-S-HHD cells. As the half-maximal binding level (BL<sub>50</sub>) values of the influenza A virus matrix protein 1-derived peptide, FMP<sub>58-66</sub> (<xref ref-type="bibr" rid="R35">35</xref>) as a high binder control and the HIV reverse transcriptase-derived peptide, HIV-pol<sub>476-484</sub> (<xref ref-type="bibr" rid="R36">36</xref>) as a medium binder control were 2.3 μM and 80.6 μM, respectively, we defined a high binder with a BL<sub>50</sub> value below 10 μM, a medium binder with a BL<sub>50</sub> value ranging from 10 to 100 μM, and a low binder with a BL<sub>50</sub> value above 100 μM. As shown in <xref ref-type="table" rid="T1">Table 1</xref>, 20 peptides were high binders, whereas 34 peptides were medium binders, suggesting that the bioinformatics prediction was mostly successful. In contrast, the remaining 28 peptides displayed low affinities or no binding to HLA-A*02:01 molecules (<xref ref-type="table" rid="T1">Table 1</xref>). In the following experiments, 54 peptides involving high binders and medium binders were chosen to further investigate their abilities of peptide-specific CTL induction.</p>
</sec>
<sec id="S4">
<title>Detection of SARS-CoV-2 pp1a-specific CD8+ T cell responses in mice immunized with peptide-encapsulated liposomes</title>
<p id="P8">Each of 54 peptides selected were encapsulated into liposomes as described in the <xref ref-type="sec" rid="S8">materials and methods</xref>. HLA-A*02:01 transgenic (HHD) mice (<xref ref-type="bibr" rid="R37">37</xref>) were then subcutaneously (s.c.) immunized twice at a one-week interval with each of peptide-encapsulated liposomes together with CpG adjuvant. One week later, spleen cells of immunized mice were prepared, stimulated <italic>in vitro</italic> with a relevant peptide for 5 hours, and stained for their expression of cell-surface CD8 and intracellular interferon-gamma (IFN-γ). As shown in <xref ref-type="fig" rid="F2">Fig. 2</xref>, the intracellular cytokine staining (ICS) assay showed that significant numbers of IFN-γ-producing CD8+ T cells were elicited in mice immunized with 18 liposomal peptides including pp1a-38, -52, -84, -103, -445, -597, -641, -1675, -2785, -2884, -3083, -3403, -3467, -3583, -3662, -3710, -3732, and -3886, revealing that these 18 peptides are HLA-A*02:01-restricted CTL epitopes derived from SARS-CoV-2 pp1a. As indicated in <xref ref-type="table" rid="T2">Table 2</xref>, multiple epitopes are located in small proteins such as nsp1 (180 aa) and nsp6 (290 aa), whereas only one epitope is seen in the large nsp3 composed of 1945 amino acids. On the other hand, the remaining 36 peptides out of 54 peptides in liposomes were not able to stimulate peptide-specific CTLs in mice (data not shown), demonstrating the necessity to generate data through wet-lab experiments. Interestingly, four epitopes including pp1a-103, -2884, -3403, and -3467 are located in the amino acid sequence of SARS-CoV pp1a as well (<xref ref-type="table" rid="T2">Table 2</xref>). pp1a-3467 was previously reported by us in the identification of SARS-CoV-derived CTL epitopes (<xref ref-type="bibr" rid="R30">30</xref>). However, any of 18 epitopes are not found in the amino acid sequence of either MERS-CoV or the four common cold human coronaviruses involving HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1.</p>
<p id="P9">In the 18 positive peptides, 10 peptides including pp1a-38, -84, -641, -1675, -2884, -3467, -3583, -3662, -3710, and -3732 were selected for the following analyses because of the high ratios of IFN-γ<sup>+</sup> cells in CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p>
</sec>
<sec id="S5">
<title>Identification of dominant CTL epitopes</title>
<p id="P10">To confirm that the 10 peptides are effective epitopes for peptide-specific CTL responses, we examined whether peptide-specific killing activities were elicited in mice with each of 10 peptides in liposomes. HHD mice were immunized s.c. twice with each of peptide-encapsulated liposomes and CpG adjuvant. One week later, equal numbers of peptide-pulsed and -unpulsed target cells were transferred into immunized mice via i.v. injection, and peptide-specific lysis was analyzed by flow cytometry. In support of the data of ICS (<xref ref-type="fig" rid="F2">Fig. 2</xref>), peptide-specific killing was observed in mice immunized with any of 10 liposomal peptides (<xref ref-type="fig" rid="F3">Fig. 3A</xref>).</p>
<p id="P11">We next attempted to identify dominant CTL epitopes among the 10 CTL epitopes. The same amounts of the 10 peptide solutions at an equal concentration were mixed together and encapsulated into liposomes. Seventeen mice were immunized once with the liposomes containing the mixture of 10 peptides. One week later, spleen cells were incubated with each of the 10 peptides for 5 hours, and the ICS assay was performed. As shown in <xref ref-type="fig" rid="F3">Fig. 3B &amp; C</xref>, pp1a-38 and -84 were statistically predominant over almost all other peptides in the induction of peptide-specific IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells. Furthermore, pp1a-641 and pp1a-3732 were significantly superior to pp1a-1675/-3583 and pp1a-1675/-3583/-3662 in the stimulation of IFN-γ-producing CD8<sup>+</sup> T cells, respectively (<xref ref-type="fig" rid="F3">Fig. 3B</xref>).</p>
<p id="P12">We also examined the peptide-specific induction of CD107a<sup>+</sup> CD8<sup>+</sup> T cells and CD69<sup>+</sup> CD8<sup>+</sup> T cells. CD107a and CD69 are markers of degranulation and early activation on CD8<sup>+</sup> T lymphocytes, respectively. Nine mice were immunized once with the liposomes encapsulating the mixture of the 10 peptides. After one week, spleen cells were stimulated with each peptide, and stained for their expression of CD107a or CD69 of CD8<sup>+</sup> T cells. At first glance, the graphs of CD107a (<xref ref-type="fig" rid="F4">Fig. 4A</xref>) and CD69 (<xref ref-type="fig" rid="F4">Fig. 4B</xref>) expression were similar to that of IFN-γ expression of CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="F3">Fig. 3C</xref>). As shown in <xref ref-type="fig" rid="F4">Figs. 4A &amp; 4C</xref>, both pp1a-38 and pp1a-84 were superior to almost all other peptides for the CD107a expression of CD8<sup>+</sup> T cells. Moreover, pp1a-641 and pp1a-3732 elicited CD107a-positive T cells better than pp1a-1675/-2884/-3467 and pp1a-1675/-2884/-3467/-3583, respectively. In the case of CD69 expression (<xref ref-type="fig" rid="F4">Figs. 4B &amp; 4D</xref>), pp1a-38 and pp1a-3732 were more dominant than pp1a-1675/-2884/-3467/-3583 and pp1a-1675/-2884/-3467/-3583/-3662, respectively. Further, pp1a-84 was superior to pp1a-1675/-2884.</p>
<p id="P13">Taken together, 10 peptides differed significantly in their ability to induce SARS-CoV-2 pp1a-specific CTLs when mice were immunized with the mixture of 10 peptides in liposomes. Thus, some peptides were found to be dominant CTL epitopes although each peptide alone of the 10 peptides has the capability to efficiently activate peptide-specific CTL (<xref ref-type="fig" rid="F2">Figs. 2</xref> &amp; <xref ref-type="fig" rid="F3">3A</xref>).</p>
</sec>
<sec id="S6">
<title>Existence of an immunodominance hierarchy</title>
<p id="P14">The data in <xref ref-type="fig" rid="F5">Fig. 5</xref> indicate reactivity to the 10 peptides in each of 15 mice immunized with the mixture of the 10 peptides in liposomes. Each graph represents reactivity of an individual mouse (<xref ref-type="fig" rid="F5">Fig. 5</xref>). Unexpectedly, all mice did not show the same reaction pattern against the 10 peptides. It looks like there were roughly three types that varied sequentially in terms of the reaction pattern to the 10 peptides. Type A is a group of mice in which pp1a-38, -84, -641-specific IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells were predominantly elicited, whereas the remaining 7 peptides were not able to activate peptide-specific IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells. In the case of type B, pp1a-3732 stimulated peptide-specific IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells as well as pp1a-38, and -84. In addition to these three peptides, several other peptides also induced IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells in Type C. These data suggest that there seems to be an immunodominance hierarchy composed of three stages in CD8<sup>+</sup> T cell responses to the 10 peptides. The immunodominance hierarchy may provide us more variations for designing CTL-based COVID-19 vaccines.</p>
</sec>
</sec>
<sec id="S7" sec-type="discussion">
<title>Discussion</title>
<p id="P15">After the epidemics of SARS and MERS, scientists have not succeeded yet in developing preventive or therapeutic vaccines available for re-emergence of them. In the SARS and MERS vaccine development, the full-length S protein or its S1 subunit have frequently been used as an antigen to produce anti-RBD neutralizing antibodies. However, these vaccine candidates provided partial protection against virus challenge in animal models accompanied by safety concerns such as ADE (<xref ref-type="bibr" rid="R1">1</xref>). Furthermore, antibody responses to coronaviruses rapidly wane following infection or immunization (<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R26">26</xref>). Considering the above, it should be necessary to consider CTL-based vaccine against SARS-CoV-2 to provide robust long-lived T cell memory although neutralizing antibody responses are a primary vaccine target.</p>
<p id="P16">In the current study, we aimed to find HLA-A*02:01-resctricted CTL dominant epitopes derived from SARS-CoV-2. Dominant epitopes induce strong immune response to eliminate a certain pathogen fast and effectively, and also contribute to make the memory T cell pool. We focused on pp1a of SARS-CoV-2 to find out CTL epitopes because pp1a is a largest and conserved polyprotein among the constituent proteins. Further, pp1a is produced earlier than structural proteins, suggesting that pp1a-specific CTLs can eliminate infected cells before the formation of mature virions. To predict CTL epitopes, we utilized bioinformatics to select 82 peptides with high scores in four kinds of computer-based programs (<xref ref-type="table" rid="T1">Table 1</xref>). In the evaluation of peptide binding, 54 peptides showed high or medium binding affinities to HLA-A*02:01 molecules, whereas the remaining 28 peptides displayed low binding affinities or no binding (<xref ref-type="table" rid="T1">Table 1</xref>). Out of them, only eighteen peptides were found to be CTL epitopes. Hence, we have to keep in mind that currently available algorithms have a limited ability to accurately predict CTL epitopes although the bioinformatics approach is very useful to quickly predict a number of epitopes in a large protein (<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R39">39</xref>).</p>
<p id="P17">Among 18 epitopes which we have identified in the current study, 4 epitopes including pp1a-103, -2884, -3403, and -3467 are present in the amino acid sequence of SARS-CoV pp1a (100% identity) (<xref ref-type="table" rid="T2">Table 2</xref>). Therefore, CTLs induced by these four epitopes could work fine for the clearance of SARS-CoV as well. In support of this data, Le Bert et al., reported that long lasting memory T cells in SARS-recovered individuals cross-reacted to N protein of SARS-CoV-2 (<xref ref-type="bibr" rid="R40">40</xref>). Recently, several studies found that SARS-CoV-2-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells were detected in a substantial proportion of healthy donors who have never infected with SARS-CoV-2 or SARS-CoV (<xref ref-type="bibr" rid="R40">40</xref>–<xref ref-type="bibr" rid="R44">44</xref>). It is most likely that these individuals were previously infected with one of the four human coronaviruses (HCoV-229E, -NL63, -OC43 and -HKU1) that cause seasonal common cold. Nelde et al. demonstrated evidence that the amino acid sequences of several SARS-CoV-2 T cell epitopes recognized by unexposed individuals are similar to some amino acid sequences in the four seasonal common cold human coronaviruses with identities ranging from 10% to 89% (not 100% identity) (<xref ref-type="bibr" rid="R44">44</xref>). However, anyone has not shown evidence that people with this cross-reactivity are less susceptible to COVID-19. It may be also possible to assume that pre-existing T cell immunity might be detrimental through mechanisms such as original antigenic sin or ADE (<xref ref-type="bibr" rid="R45">45</xref>). In the current data, any of the 18 epitopes was not found in the amino acid sequences of the four human coronaviruses, suggesting that effective common CTL epitopes derived from pp1a, if any, might be very few.</p>
<p id="P18">Here, we focused on CTL epitopes restricted by HLA-A*02:01 which is the most common HLA class I allele in the world, and used highly reactive HLA-A*02:01 transgenic mice, termed HHD mice (<xref ref-type="bibr" rid="R37">37</xref>). Although we can use lymphocytes of SARS-CoV-2-infected individuals to identify CTL epitopes, there are mainly two advantages to using HHD mice. First, a large amount of blood of patients is required for examine many candidates of CTL epitopes, but any number of mice can be prepared for this purpose. Second, when using patients’ lymphocytes, we are only testing whether the peptide candidates are recognized by memory CTLs. When using naïve mice, however, we can find whether the epitope candidates are able to prime peptide-specific CTLs, which may be a better criterion to judge them as vaccine antigens. It is supposed that the efficient epitope for CTL recognition is not always efficient for CTL priming. However, we should take into account that the immunogenic variation in HLA class I transgenic mice may not be identical to that in humans because the antigen processing and presentation differ between them.</p>
<p id="P19">In the previous studies, we used peptide-linked liposomes as an immunogen (<xref ref-type="bibr" rid="R30">30</xref>). The surface-linked liposomal peptides were effective for peptide-specific CTL induction in mice. However, attaching peptides to the surface of liposomes followed by purifying them through the column is a fairly complicated process and time-consuming. In the current study, peptide-encapsulated liposomes were used as an immunogen. In contrast to the peptide-linked liposomes, the peptide-encapsulated liposomes are prepared by just mixing liposomes and the peptide. In addition, the peptide-encapsulated liposomes are able to prime peptide-specific CTLs in mice as efficiently as the peptide-linked liposomes. Liposome itself consisting of lipid bilayers is a very safe material for humans. Therefore, the peptide-encapsulated liposomes are considered to be promising as a CTL-based vaccine candidate.</p>
<p id="P20">Understanding the mechanism of immunodominance is obviously important for the development of effective vaccines. When mice were immunized with liposomes containing the mixture of 10 peptides, it was found that some peptides induced peptide-specific CTLs stronger than other peptides (<xref ref-type="fig" rid="F3">Figs. 3</xref> &amp; <xref ref-type="fig" rid="F4">4</xref>). As shown in <xref ref-type="fig" rid="F3">Figs. 3</xref> &amp; <xref ref-type="fig" rid="F4">4</xref>, pp1a-38 and -84 are considered to be relatively dominant in comparison with other peptides. In general, dominant epitope-specific CTLs are activated sooner and proliferate faster than subdominant epitope-specific CTLs. This immunodominance may be associated with the affinity of peptide to MHC-I molecules and the affinity of T-cell receptor (TCR) to the peptide-MHC-I complex. As shown in <xref ref-type="table" rid="T1">Table I</xref>, the peptide affinity of pp1a-84 to HLA-A*02:01 is very high (BL<sub>50</sub> = 6.8 μM), while pp1a-38 is a medium binder (BL<sub>50</sub> = 76.8 μM). Interestingly, the peptide affinity of pp1a-38 is lowest among the 10 peptides selected (<xref ref-type="table" rid="T1">Table I</xref>). These data suggest that the affinity of TCR to the peptide-MHC-I complex is critical for CTL immunodominance. In the selection of antigenic epitopes for the CTL-based vaccine against SARS-CoV-2, dominant epitopes such as pp1a-38 and -84 should be chosen because they produce strong CTL response to eliminate virus-infected cells effectively. However, the immunological pressure exerted by dominant epitopes may allow the epitope sequences of SARS-CoV-2 to be mutated, and therefore, a vaccine containing multiple antigenic epitopes should be recommended for a successful COVID-19 vaccine.</p>
<p id="P21">It was surprising that all of the genetically identical mice did not show the same reactive pattern against the 10 peptides when they were immunized with liposomes containing the mixture of 10 peptides (<xref ref-type="fig" rid="F5">Fig. 5</xref>). There were roughly three pattern types, A-C, that varied sequentially, suggesting the existence of an immunodominance hierarchy composed of three stages in CD8<sup>+</sup> T cell responses to the 10 peptides (<xref ref-type="fig" rid="F5">Fig. 5</xref>). The differences among the three types might be explained by the timing of CTL expansion. In the type A, dominant peptides, pp1a-38, -84, and -641 presumably activated T cells more efficiently than the other peptides, and hence, dominant peptide-specific CTLs proliferate faster and curtail the expansion of CTLs specific for the other peptides. In the type B, it is considered that the expansion of dominant CTLs specific for pp1a-38, and -84 was delayed for some reason compared to that in type A, and thereby subdominant CTLs specific for pp1a-3732 could afford to expand. It is also thought that even non-dominant CTLs proliferated because the expansion of both dominant CTLs and subdominant CTLs in the type C was later than that in the type B. Although it is difficult to explain what caused difference in the timing of CTL expansion among three reaction types, it should be important to find out what it is for the development of CTL-based peptide vaccine.</p>
<p id="P22">In summary, we have identified 18 kinds of HLA-A*02:01-restricted CTL epitopes derived from pp1a of SARS-CoV-2 using computational algorithms, HLA-A*02:01 transgenic mice and the peptide-encapsulated liposomes. Out of 18 epitopes, we have also found some dominant CTL epitopes such as pp1a-38 and -84. In the process of finding dominant epitopes, we showed the existence of an immunodominance hierarchy in CD8<sup>+</sup> T cell responses to these epitopes. The immunodominance hierarchy composed of multiple stages may offer us more variations in the epitope selection for designing CTL-based COVID-19 vaccines. These data may provide important information for further studies of T cell immunity in COVID-19 and the development of preventive and/or therapeutic CTL-based vaccines against SARS-CoV-2.</p>
</sec>
<sec id="S8" sec-type="materials | methods">
<title>Materials and Methods</title>
<sec id="S9">
<title>Prediction of CTL epitopes</title>
<p id="P23">Four computer-based programs including SYFPEITHI (<xref ref-type="bibr" rid="R31">31</xref>), nHLAPred (<xref ref-type="bibr" rid="R32">32</xref>), ProPred-I (<xref ref-type="bibr" rid="R33">33</xref>), and IEDB (<xref ref-type="bibr" rid="R34">34</xref>) were used to predict HLA-A*02:01-restricted CTL epitopes derived from pp1a of SARS-CoV-2 (GenBank accession numbers: LC528232.1 &amp; LC528233.1). As shown in <xref ref-type="table" rid="T1">Table 1</xref>, 82 peptides with superior scores were selected and were synthesized by Eurofins Genomics (Tokyo, Japan). Two control peptides, FMP<sub>58-66</sub> (sequence: GILFGVFTL) (<xref ref-type="bibr" rid="R35">35</xref>) and HIV-pol<sub>476-484</sub> (sequence: ILKEPVHGV) (<xref ref-type="bibr" rid="R36">36</xref>), were synthesized as well.</p>
</sec>
<sec id="S10">
<title>Mice</title>
<p id="P24">We used HLA-A*02:01 transgenic mice (<xref ref-type="bibr" rid="R37">37</xref>) that express a transgenic HLA-A*02:01 monochain, designated as HHD, in which human β2-microglobulin is covalently linked to a chimeric heavy chain composed of HLA-A*02:01 (α1 and α2 domains) and H-2D<sup>b</sup> (α3, transmembrane, and cytoplasmic domains). Six- to ten-week-old mice were used for all experiments. Mice were housed in appropriate animal care facilities at Saitama Medical University, and were handled according to the international guideline for experiments with animals. This study was approved by the Animal Research Committee of Saitama Medical University.</p>
</sec>
<sec id="S11">
<title>Cell lines</title>
<p id="P25">RMA-S-HHD is a TAP2-dificient mouse lymphoma cell line, RMA-S (H-2<sup>b</sup>) transfected with the HHD gene (<xref ref-type="bibr" rid="R37">37</xref>). RMA-S-HHD was cultured in RPMI-1640 medium (Nacalai Tesque Inc., Kyoto, Japan) with 10% FCS (Biowest, Nuaille, France) and 500 μg/ml G418 (Nacalai Tesque Inc.)</p>
</sec>
<sec id="S12">
<title>Peptide binding assay</title>
<p id="P26">Binding of peptides to the HLA-A*02:01 molecule was measured using RMA-S-HHD cells, as described (<xref ref-type="bibr" rid="R46">46</xref>). Briefly, RMA-S-HHD cells were pre-cultured overnight at 26°C in a CO<sub>2</sub> incubator, and then pulsed with each peptide at various concentrations ranging from 0.01 μM to 100 μM for 1 hour at 26°C. After 3 hours’ incubation at 37°C, peptide-pulsed cells were stained with anti-HLA-A2 monoclonal antibody, BB7.2 (<xref ref-type="bibr" rid="R47">47</xref>), followed by FITC-labeled goat anti-mouse IgG antibody (Sigma-Aldrich, St. Louis, MO). Mean fluorescence intensity (MFI) of HLA-A2 expression on the surface of RMA-S-HHD cells was measured by flow cytometry (FACSCanto™ II, BD Biosciences, Franklin Lakes, NJ), and standardized as the percent cell surface expression by the following formula: % relative binding = [{(MFI of cells pulsed with each peptide) – (MFI of cells incubated at 37°C without a peptide)}/{(MFI of cells incubated at 26°C without a peptide) – (MFI of cells incubated at 37°C without a peptide)}] × 100. The concentration of each peptide that yields the 50% relative binding was calculated as the half-maximal binding level (BL<sub>50</sub>). FMP<sub>58-66</sub> and HIV-pol<sub>476-484</sub> were used as control peptides.</p>
</sec>
<sec id="S13">
<title>Peptide-encapsulated liposomes</title>
<p id="P27">Peptide-encapsulated liposomes were prepared using Lipocapsulater FD-U PL (Hygieia BioScience, Osaka, Japan) according to the manufacturer’s instructions with a slight modification. In brief, each of 54 synthetic peptides was dissolved in DMSO at a final concentration of 10 mM. For the first screening, the same amounts of 4 to 5 kinds of 10 mM peptides were mixed to make a total 100 μl, which was then diluted with 1.9 ml of H<sub>2</sub>O. For the second screening, 20 μl of each peptide at 10 mM was diluted to 2 ml with H<sub>2</sub>O. For the identification of dominant epitopes among the 10 peptides selected, 20 μl of each of the 10 peptide solutions at a concentration of 10 mM was mixed together, and the total volume was increased to 2 ml by adding 1.8 ml of H<sub>2</sub>O. The peptide solution was added into a vial of Lipocapsulater containing 10 mg of dried liposomes, and incubated for 15 min at room temperature. The resultant solution contains peptide-encapsulated liposomes.</p>
</sec>
<sec id="S14">
<title>Immunization</title>
<p id="P28">Mice were immunized s.c. once or twice at a one-week interval with peptide-encapsulated liposomes (100 μl/mouse) together with CpG-ODN (5002: 5’-TCCATGACGTTCTTGATGTT-3’, Hokkaido System Science, Sapporo, Japan) (5 μg/mouse) in the footpad.</p>
</sec>
<sec id="S15">
<title>Intracellular cytokine staining (ICS)</title>
<p id="P29">ICS was performed as described (<xref ref-type="bibr" rid="R30">30</xref>). In brief, after 1 wk following immunization, spleen cells were incubated with 50 μM of each peptide for 5 hours at 37°C in the presence of brefeldin A (GolgiPlug™, BD Biosciences), and were stained with FITC-conjugated anti-mouse CD8 monoclonal antibody (mAb) (BioLegend, San Diego, CA). Cells were then fixed, permeabilized, and stained with phycoerythrin (PE)-conjugated rat anti-mouse IFN-γ mAb (BD Biosciences). After washing the cells, flow cytometric analyses were performed using flow cytometry (FACSCanto™ II, BD Biosciences).</p>
</sec>
<sec id="S16">
<title>Detection of CD107a and CD69 molecules on CD8<sup>+</sup> T cells</title>
<p id="P30">For the detection of CD107a, spleen cells of immunized mice were incubated with 50 μM of each peptide for 6 hours at 37°C in the presence of monensin (GolgiStop™, BD Biosciences) and 0.8 μg of FITC-conjugated anti-mouse CD107a mAb (BioLegend). Cells were then stained with PE-Cy5-conjugated anti-mouse CD8 mAb (BioLegend). For the examination of CD69 marker, spleen cells of immunized mice were stimulated with 50 μM of each peptide for 4 hours at 37°C. Cells were then stained with PE-conjugated anti-mouse CD69 mAb (BioLegend) and FITC-conjugated anti-mouse CD8 mAb. Stained cells were analyzed by flow cytometry (FACSCanto™ II, BD Biosciences).</p>
</sec>
<sec id="S17">
<title>
<italic>In vivo</italic> CTL assay</title>
<p id="P31">
<italic>In vivo</italic> CTL assay was carried out as described (<xref ref-type="bibr" rid="R46">46</xref>). In brief, spleen cells from naive HHD mice were equally split into two populations. One population was pulsed with 50 μM of a relevant peptide and labeled with a high concentration (2.5 μM) of carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR). The other population was unpulsed and labeled with a lower concentration (0.25 μM) of CFSE. An equal number (1 × 10<sup>7</sup>) of cells from each population was mixed together and adoptively transferred i.v. into mice that had been immunized once with a liposomal peptide. Sixteen hours later, spleen cells were prepared and analyzed by flow cytometry. To calculate specific lysis, the following formula was used: % specific lysis = [1-{(number of CFSE<sup>low</sup> cells in normal mice)/(number of CFSE<sup>high</sup> cells in normal mice)}/{(number of CFSE<sup>low</sup> cells in immunized mice)/(number of CFSE<sup>high</sup> cells in immunized mice)}] × 100.</p>
</sec>
<sec id="S18">
<title>Statistical analyses</title>
<p id="P32">One-way ANOVA followed by post-hoc tests was performed for statistical analyses among multiple groups using Graphpad Prism 5 software (GraphPad software, San Diego, CA). A value of <italic>P</italic> &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
</body>
<back>
<ack id="S19">
<title>Acknowledgments</title>
<p>The authors are grateful to Professor François A. Lemonnier (Pasteur Institute, Paris, France) for providing HHD mice and RMA-S-HHD cells. This work was supported by a Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI Grant Number: JP18K06631) to M. M., a Grant-in-Aid for Early-Career Scientists (JSPS KAKENHI Grant Number: JP18K15430) to A. T. from Japan Society for the Promotion of Science, and a Grant from Ochiai memorial award 2018 to A. T. The authors have no conflicting financial interests.</p>
</ack>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sariol</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Lessons for COVID-19 immunity from other coronavirus infections</article-title>
<source>Immunity</source>
<year>2020</year>
<volume>53</volume>
<fpage>248</fpage>
<lpage>263</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mkandawire</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Narykov</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Korkin</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
<fpage>360</fpage>
<pub-id pub-id-type="doi">10.3390/v12040360</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wall</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
</person-group>
<source>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>281</fpage>
<lpage>292</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kleine-Weber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krüger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Herrler</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Erichsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schiergens</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Herrler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Nitsche</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>271</fpage>
<lpage>280</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thevarajan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>THO</given-names>
</name>
<name>
<surname>Koutsakos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Druce</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Caly</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van de Sandt</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Catton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cowie</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>SYC</given-names>
</name>
<etal/>
</person-group>
<article-title>Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19</article-title>
<source>Nat Med</source>
<year>2020</year>
<volume>26</volume>
<fpage>453</fpage>
<lpage>455</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>77</fpage>
<lpage>81</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guebre-Xabier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J-H</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Maciejewski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Portnoff</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Massare</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Frieman</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Piedra</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Ellingsworth</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.08.18.256578</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Frenck</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Falsey</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Kitchin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Absalon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gurtman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lockhart</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Neuzil</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mulligan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>KA</given-names>
</name>
<etal/>
</person-group>
<article-title>RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study</article-title>
<source>medRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.08.17.20176651</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tostanoski</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mercado</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>McMahan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mahrokhian</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Nkolola</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chandrashekar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>DR</given-names>
</name>
<etal/>
</person-group>
<article-title>DNA vaccine protection against SARS-CoV-2 in rhesus macaques</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>806</fpage>
<lpage>811</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassan</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Kafai</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Dmitriev</surname>
<given-names>IP</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Wessel</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Kashentseva</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2</article-title>
<source>Cell</source>
<year>2020</year>
<month>August</month>
<day>14</day>
<pub-id pub-id-type="doi">10.1016/j.cell.2020.08.026</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The potential danger of suboptimal antibody responses in COVID-19</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<fpage>339</fpage>
<lpage>341</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arvin</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cathcart</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spreafico</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Havenar-Daughton</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lanzavecchia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Corti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Virgin</surname>
<given-names>HW</given-names>
</name>
</person-group>
<article-title>A perspective on potential antibody-dependent enhancement of SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>353</fpage>
<lpage>363</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weingart</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Czub</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Czub</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Neufeld</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marszal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Proulx</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Deschambault</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Grudeski</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</article-title>
<source>J Virol</source>
<year>2004</year>
<volume>78</volume>
<fpage>12672</fpage>
<lpage>12676</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tseng</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Sbrana</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Iwata-Yoshikawa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Garron</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Atmar</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Couch</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title>
<source>PLoS One</source>
<year>2012</year>
<volume>7</volume>
<fpage>e35421</fpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title>
<source>Biochem Biophys Res Commn</source>
<year>2014</year>
<volume>451</volume>
<fpage>208</fpage>
<lpage>214</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nishiura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title>
<source>JCI Insight</source>
<year>2019</year>
<volume>4</volume>
<fpage>e123158</fpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JCC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agudelo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Gazumyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hägglöf</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>437</fpage>
<lpage>442</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juno</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H-X</given-names>
</name>
<name>
<surname>Reynaldi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Wragg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Esterbauer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kent</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Batten</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mordant</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Gherardin</surname>
<given-names>NA</given-names>
</name>
<etal/>
</person-group>
<source>Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19</source>
<year>2020</year>
<month>July</month>
<day>13</day>
<pub-id pub-id-type="doi">10.1038/s41591-020-0995-0</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jaconi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Culap</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-neutralization of SARS-COV-2 by a human monoclonal SARS-CoV antibody</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<fpage>290</fpage>
<lpage>295</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JF-W</given-names>
</name>
<name>
<surname>Sahi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Figueroa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>XV</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>450</fpage>
<lpage>456</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Nkolola</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reidy</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Trivette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nargi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>
<article-title>Potently neutralizing and protective human antibodies against SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>443</fpage>
<lpage>449</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ledford</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Antibody therapies could be a bridge to a coronavirus vaccine-but will the world benefit?</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>333</fpage>
<lpage>334</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>W-C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P-H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Richardus</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Disappearance of antibodies to SARS-associated coronavirus after recovery</article-title>
<source>N Engl J Med</source>
<year>2007</year>
<volume>357</volume>
<fpage>1162</fpage>
<lpage>1163</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chan-Yeung</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance</article-title>
<source>Respirology</source>
<year>2006</year>
<volume>11</volume>
<fpage>49</fpage>
<lpage>53</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ng</surname>
<given-names>OW</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Jadi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Leong</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Bertoletti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>YJ</given-names>
</name>
</person-group>
<article-title>Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection</article-title>
<source>Vaccine</source>
<year>2016</year>
<volume>34</volume>
<fpage>2008</fpage>
<lpage>2014</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Merrick</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Acors</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Steel</surname>
<given-names>KJA</given-names>
</name>
<name>
<surname>Hemmings</surname>
<given-names>O</given-names>
</name>
<name>
<surname>O’Bryne</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kouphou</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pickering</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Galao</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Betancor</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>Logitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection</article-title>
<source>medRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.07.09.20148429</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19</article-title>
<source>Front immunol</source>
<year>2020</year>
<volume>11</volume>
<fpage>1729</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2020.01729</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>TBR</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sundaram</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ellingson</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Israelow</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Longitudinal analyses reveal immunological misfiring in severe COVID-19</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>463</fpage>
<lpage>469</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>ZL</given-names>
</name>
</person-group>
<article-title>Origin and evolution of pathogenic coronaviruses</article-title>
<source>Nat Rev Microbiol</source>
<year>2019</year>
<volume>17</volume>
<fpage>181</fpage>
<lpage>192</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tatsuya</surname>
<given-names>Suda T</given-names>
</name>
<name>
<surname>Taneichi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tetsuya Uchida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsui</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a</article-title>
<source>Antiviral Res</source>
<year>2009</year>
<volume>84</volume>
<fpage>168</fpage>
<lpage>177</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rammensee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bachmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Emmerich</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Bachor</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Stevanović</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>SYFPEITHI: database for MHC ligands and peptide motifs</article-title>
<source>Immunogenetics</source>
<year>1999</year>
<volume>50</volume>
<fpage>213</fpage>
<lpage>219</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhasin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raghava</surname>
<given-names>GPS</given-names>
</name>
</person-group>
<article-title>A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes</article-title>
<source>J Biosci</source>
<year>2006</year>
<volume>32</volume>
<fpage>31</fpage>
<lpage>42</lpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Raghava</surname>
<given-names>GPS</given-names>
</name>
</person-group>
<article-title>ProPred1: Prediction of promiscuous MHC class-I binding sites</article-title>
<source>Bioinformatics</source>
<year>2003</year>
<volume>19</volume>
<fpage>1009</fpage>
<lpage>1014</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vita</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Overton</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Dhanda</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cantrell</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Sette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The immune epitope database (IEDB): 2018 update</article-title>
<source>Nucleic Acids Res</source>
<year>2019</year>
<volume>47</volume>
<issue>D1</issue>
<fpage>D339</fpage>
<lpage>D343</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gky1006</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gotch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rothbard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Howland</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McMichael</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2</article-title>
<source>Nature</source>
<year>1987</year>
<volume>326</volume>
<fpage>881</fpage>
<lpage>882</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsomides</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Eisen</surname>
<given-names>HN</given-names>
</name>
</person-group>
<article-title>An optimal viral peptide recognized by CD8<sup>+</sup> T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>1991</year>
<volume>88</volume>
<fpage>11276</fpage>
<lpage>11280</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pascolo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bervas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ure</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Lemonnier</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Pérarnau</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>HLA-A2.1-restricted education and cytolytic activity of CD8<sup>+</sup> T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2D<sup>b</sup> beta2m double knockout mice</article-title>
<source>J Exp Med</source>
<year>1997</year>
<volume>185</volume>
<fpage>2043</fpage>
<lpage>2051</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sidney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Scheuermann</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sette</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A sequence homology and bioinformatics approach can predict candidate targets for immune responses to SARS-CoV-2</article-title>
<source>Cell Host &amp; Microbe</source>
<year>2020</year>
<volume>27</volume>
<fpage>671</fpage>
<lpage>680</lpage>
<comment>2020</comment>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ong</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>MU</given-names>
</name>
<name>
<surname>Huffman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning</article-title>
<source>Front Immunol</source>
<volume>11</volume>
<fpage>1581</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2020.01581</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Bert</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Kunasegaran</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tham</surname>
<given-names>CYL</given-names>
</name>
<name>
<surname>Hafezi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chng</surname>
<given-names>MHY</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Linster</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>WN</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>457</fpage>
<lpage>462</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mateus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tarke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>John Sidney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>ZC</given-names>
</name>
<name>
<surname>Rawlings</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mallal</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title>
<source>Science</source>
<year>2020</year>
<month>August</month>
<day>4</day>
<fpage>eabd3871</fpage>
<comment>2020</comment>
<pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weiskopf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Mateus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Moderbacher</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Rawlings</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Premkumar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jadi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Marrama</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>1489</fpage>
<lpage>1501</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Loyal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frentsch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wendisch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Georg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hippenstiel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dingeldey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kruse</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fauchere</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baysal</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</article-title>
<source>Nature</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1038/s41586-020-2598-9</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelde</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bilich</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Heitmann</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Maringer</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Salih</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Roerden</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lübke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jonas Rieth</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wacker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-epitopes define heterologous and COVID-19-induced T-cell recognition</article-title>
<source>Research Square</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.21203/rs.3.rs-35331/v1</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Crotty</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Pre-existing immunity to SARS-CoV-2: the knowns and unknowns</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<fpage>457</fpage>
<lpage>458</lpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kawano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Akatsuka</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity</article-title>
<source>Mol Ther Methods Clin Dev</source>
<year>2014</year>
<volume>1</volume>
<comment>14027</comment>
<pub-id pub-id-type="doi">10.1038/mtm.2014.27</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parham</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brodsky</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28</article-title>
<source>Hum Immunol</source>
<year>1981</year>
<volume>3</volume>
<fpage>277</fpage>
<lpage>299</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<boxed-text id="BX1" position="float" orientation="portrait">
<caption>
<title>Importance</title>
</caption>
<p>For the development of vaccines based on SARS-CoV-2-specific cytotoxic T lymphocytes (CTLs), we attempted to identify HLA-A*02:01-restricted CTL epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2. Out of 82 peptides predicted on bioinformatics, 54 peptides showed good binding affinities to HLA-A*02:01. Using HLA-A*02:01 transgenic mice, 18 in 54 peptides were found to be CTL epitopes in the intracellular cytokine staining assay. Out of 18 peptides, 10 peptides were chosen for the following analyses because of their high responses. To identify dominant epitopes, mice were immunized with liposomes containing the mixture of the 10 peptides. Some peptides were shown to be statistically predominant. Surprisingly, all immunized mice did not show the same reaction pattern to the 10 peptides. There were three pattern types that varied sequentially, suggesting the existence of an immunodominance hierarchy, which may provide us more variations in the epitope selection for designing CTL-based COVID-19 vaccines.</p>
</boxed-text>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<p>The linear diagrams of the SARS-CoV-2 genome and the protein subunits of ORF1a. The SARS-CoV-2 genome consists of ORF1a, ORF1b, Spike (S), ORF3a, Envelope (E), Membrane (M), ORF6, ORF7a, ORF7b, ORF8, Nucleocapsid (N), and ORF10. The ORF1a polyprotein is composed of eleven non-structural proteins, nsp1-nsp11.</p>
</caption>
<graphic xlink:href="EMS97964-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<p>Intracellular IFN-γ staining of CD8<sup>+</sup> T cells specific for peptides derived from SARS-CoV-2 pp1a. HHD mice were immunized twice with each of predicted peptides of SARS-CoV-2 pp1a in liposomes together with CpG. After one week, spleen cells were prepared and stimulated with (+) or without (-) a relevant peptide for 5 hours. Cells were then stained for their surface expression of CD8 (x axis) and their intracellular expression of IFN-γ (y axis). The numbers shown indicate the percentages of intracellular IFN-γ<sup>+</sup> cells within CD8<sup>+</sup> T cells. Three to five mice per group were used in each experiment, and the spleen cells of the mice per group were pooled.</p>
</caption>
<graphic xlink:href="EMS97964-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<p>(A) <italic>In vivo</italic> killing activities specific for the 10 peptides. HHD mice were immunized twice with either each of the 10 liposomal peptides (pp1a-38, -84, -641, -1675, -2884, -3467, -3583, -3662, 3710, and -3732) or liposomes alone together with CpG. One week later, <italic>in vivo</italic> peptide-specific killing activities were measured. Three to five mice per group were used, and the data of % specific lysis are shown as the mean ± SD. (B &amp; C) Comparison of the 10 peptides in the induction of IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells. Seventeen HHD mice were immunized once with the mixture of 10 peptides involving pp1a-38, -84, -641, -1675, -2884, -3467, -3583, -3662, -3710, and -3732 in liposomes with CpG. After one week, spleen cells were stimulated with or without each of the 10 peptides, and intracellular IFN-γ in CD8+ T cells was stained. (C) Y-axis indicates the relative percentages of IFN-γ<sup>+</sup> cells in CD8<sup>+</sup> T cells which were calculated by subtracting the % of IFN-γ<sup>+</sup> cells in CD8<sup>+</sup> T cells without a peptide from the % of IFN-γ<sup>+</sup> cells in CD8<sup>+</sup> T cells with a relevant peptide. Each blue circle represents an individual mouse. Data are shown as the mean (horizontal bars) ± SD. (B) Statistical comparisons of the relative % values of IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells among the 10 peptides in <xref ref-type="fig" rid="F3">Fig. 3C</xref> were made by one-way ANOVA followed by post-hoc tests. *, <italic>P</italic> &lt; 0.05; **, <italic>P</italic> &lt; 0.01; ***, <italic>P</italic> &lt; 0.001; ns, not significant.</p>
</caption>
<graphic xlink:href="EMS97964-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig. 4</label>
<caption>
<p>Comparison of the 10 peptides in the induction of CD107a<sup>+</sup> CD8<sup>+</sup> T cells (A) and CD69<sup>+</sup> CD8<sup>+</sup> T cells (B). Nine HHD mice were immunized once with the mixture of 10 peptides involving pp1a-38, -84, -641, -1675, -2884, -3467, -3583, -3662, -3710, and -3732 in liposomes with CpG. After one week, spleen cells were stimulated with or without each of the 10 peptides, and the expression of CD107a (A) or CD69 (B) on CD8+ T cells was analyzed. Data indicates the relative percentages of CD107a<sup>+</sup> (A) and CD69<sup>+</sup> (B) cells in CD8<sup>+</sup> T cells which were obtained by subtracting the % of CD107a<sup>+</sup> and CD69<sup>+</sup> cells in CD8<sup>+</sup> T cells without a peptide from the % of CD107a<sup>+</sup> and CD69<sup>+</sup> cells in CD8<sup>+</sup> T cells with a peptide, respectively. Each red (A) or green (B) circle represents an individual mouse. Data are shown as the mean (horizontal bars) ± SD. Statistical analyses of the data among the 10 peptides in <xref ref-type="fig" rid="F4">Fig. 4A and Fig. 4B</xref> were performed by one-way ANOVA followed by post-hoc tests in <xref ref-type="fig" rid="F4">Fig. 4C and Fig 4D</xref>, respectively. *, <italic>P</italic> &lt; 0.05; **, <italic>P</italic> &lt; 0.01; ***, <italic>P</italic> &lt; 0.001; ns, not significant.</p>
</caption>
<graphic xlink:href="EMS97964-f004"/>
</fig>
<fig id="F5" position="float">
<label>Fig. 5</label>
<caption>
<p>Three types of reactivity in mice immunized with the mixture of the 10 peptides. Fifteen mice were immunized once with the mixture of 10 peptides including pp1a-38, -84, -641, -1675, -2884, -3467, -3583, -3662, -3710, and -3732 in liposomes with CpG. After one week, spleen cells were stimulated with or without each of the 10 peptides, and intracellular IFN-γ in CD8+ T cells was stained. Based on the reactivity pattern to the 10 peptides, fifteen mice were divided into three types, A-C. Each graph represents reactivity of an individual mouse. Y-axis indicates the relative percentage of IFN-γ<sup>+</sup> cells in CD8<sup>+</sup> T cells which was calculated by subtracting the % of IFN-γ<sup>+</sup> cells in CD8<sup>+</sup> T cells without a peptide from the % of IFN-γ<sup>+</sup> cells in CD8<sup>+</sup> T cells with a relevant peptide. Statistical analyses of the relative % values to 10 peptides in each type were performed by one-way ANOVA followed by post-hoc tests. *, <italic>P</italic> &lt; 0.05; **, <italic>P</italic> &lt; 0.01; ***, <italic>P</italic> &lt; 0.001; ns, not significant.</p>
</caption>
<graphic xlink:href="EMS97964-f005"/>
</fig>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Predicted CTL epitopes for the SARS-CoV-2 non-structural polyprotein 1a</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="top" colspan="6">High binders</th>
</tr>
<tr style="border-top: solid thin">
<th align="center" valign="top">Name</th>
<th align="center" valign="top">Sequence</th>
<th align="center" valign="top">BL<sub>50</sub>
</th>
<th align="center" valign="top">Name</th>
<th align="center" valign="top">Sequence</th>
<th align="center" valign="top">BL<sub>50</sub>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="top">pp1a-84</td>
<td align="center" valign="top">VMVELVAEL</td>
<td align="center" valign="top">6.8 ± 0.3</td>
<td align="center" valign="top">pp1a-103</td>
<td align="center" valign="top">TLGVLVPHV</td>
<td align="center" valign="top">1.3 ± 0.2</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-214</td>
<td align="center" valign="top">TLSEQLDFI</td>
<td align="center" valign="top">2.0 ± 0.2</td>
<td align="center" valign="top">pp1a-445</td>
<td align="center" valign="top">GLNDNLLEI</td>
<td align="center" valign="top">6.0 ± 0.2</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-597</td>
<td align="center" valign="top">VMAYITGGV</td>
<td align="center" valign="top">9.5 ± 0.9</td>
<td align="center" valign="top">pp1a-619</td>
<td align="center" valign="top">TVYEKLKPV</td>
<td align="center" valign="top">5.6 ± 0.7</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-641</td>
<td align="center" valign="top">FLRDGWEIV</td>
<td align="center" valign="top">0.9 ± 0.1</td>
<td align="center" valign="top">pp1a-1675</td>
<td align="center" valign="top">YLATALLTL</td>
<td align="center" valign="top">8.4 ± 0.2</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2270</td>
<td align="center" valign="top">YLNSTNVTI</td>
<td align="center" valign="top">8.9 ± 0.3</td>
<td align="center" valign="top">pp1a-2569</td>
<td align="center" valign="top">ILLLDQALV</td>
<td align="center" valign="top">9.6 ± 1.5</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2785</td>
<td align="center" valign="top">AIFYLITPV</td>
<td align="center" valign="top">5.1 ± 1.6</td>
<td align="center" valign="top">pp1a-2968</td>
<td align="center" valign="top">YLEGSVRVV</td>
<td align="center" valign="top">7.5 ± 0.1</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3013</td>
<td align="center" valign="top">SLPGVFCGV</td>
<td align="center" valign="top">3.1 ± 0.2</td>
<td align="center" valign="top">pp1a-3115</td>
<td align="center" valign="top">YLTNDVSFL</td>
<td align="center" valign="top">4.8 ± 0.3</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3122</td>
<td align="center" valign="top">FLAHIQWMV</td>
<td align="center" valign="top">6.9 ± 0.4</td>
<td align="center" valign="top">pp1a-3128</td>
<td align="center" valign="top">WMVMFTPLV</td>
<td align="center" valign="top">9.8 ± 1.1</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3587</td>
<td align="center" valign="top">ILTSLLVLV</td>
<td align="center" valign="top">8.3 ± 0.9</td>
<td align="center" valign="top">pp1a-3710</td>
<td align="center" valign="top">TLMNVLTLV</td>
<td align="center" valign="top">2.0 ± 0.4</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3732</td>
<td align="center" valign="top">SMWALIISV</td>
<td align="center" valign="top">8.9 ± 0.4</td>
<td align="center" valign="top">pp1a-4094</td>
<td align="center" valign="top">ALWEIQQVV</td>
<td align="center" valign="top">6.4 ± 0.4</td>
</tr>
<tr style="border-top: solid thin">
<td align="center" valign="top" colspan="6">Medium binders</td>
</tr>
<tr style="border-top: solid thin">
<td align="center" valign="top">Name</td>
<td align="center" valign="top">Sequence</td>
<td align="center" valign="top">BL<sub>50</sub>
</td>
<td align="center" valign="top">Name</td>
<td align="center" valign="top">Sequence</td>
<td align="center" valign="top">BL<sub>50</sub>
</td>
</tr>
<tr style="border-top: solid thin">
<td align="center" valign="top">pp1a-15</td>
<td align="center" valign="top">QLSLPVLQV</td>
<td align="center" valign="top">79.4 ± 4.4</td>
<td align="center" valign="top">pp1a-38</td>
<td align="center" valign="top">VLSEARQHL</td>
<td align="center" valign="top">76.8 ± 6.8</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-52</td>
<td align="center" valign="top">GLVEVEKGV</td>
<td align="center" valign="top">14.5 ± 4.9</td>
<td align="center" valign="top">pp1a-106</td>
<td align="center" valign="top">VLVPHVGEI</td>
<td align="center" valign="top">76.0 ± 2.0</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-468</td>
<td align="center" valign="top">KLNEEIAII</td>
<td align="center" valign="top">56.2 ± 4.8</td>
<td align="center" valign="top">pp1a-600</td>
<td align="center" valign="top">YITGGVVQL</td>
<td align="center" valign="top">48.5 ± 7.9</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-685</td>
<td align="center" valign="top">FLALCADSI</td>
<td align="center" valign="top">10.2 ± 0.5</td>
<td align="center" valign="top">pp1a-702</td>
<td align="center" valign="top">ALNLGETFV</td>
<td align="center" valign="top">40.7 ± 2.8</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-1109</td>
<td align="center" valign="top">NLAKHCLHV</td>
<td align="center" valign="top">38.5 ± 8.2</td>
<td align="center" valign="top">pp1a-1114</td>
<td align="center" valign="top">CLHVVGPNV</td>
<td align="center" valign="top">62.9 ± 2.3</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-1161</td>
<td align="center" valign="top">SLRVCVDTV</td>
<td align="center" valign="top">85.7 ± 1.9</td>
<td align="center" valign="top">pp1a-1312</td>
<td align="center" valign="top">MLAKALRKV</td>
<td align="center" valign="top">95.2 ± 0.7</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2168</td>
<td align="center" valign="top">YMPYFFTLL</td>
<td align="center" valign="top">99.0 ± 2.4</td>
<td align="center" valign="top">pp1a-2332</td>
<td align="center" valign="top">ILFTRFFYV</td>
<td align="center" valign="top">96.5 ± 14.0</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2563</td>
<td align="center" valign="top">QLMCQPILL</td>
<td align="center" valign="top">11.1 ± 1.8</td>
<td align="center" valign="top">pp1a-2884</td>
<td align="center" valign="top">FLPRVFSAV</td>
<td align="center" valign="top">29.3 ± 6.5</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3047</td>
<td align="center" valign="top">IVAGGIVAI</td>
<td align="center" valign="top">50.5 ± 2.5</td>
<td align="center" valign="top">pp1a-3083</td>
<td align="center" valign="top">LLFLMSFTV</td>
<td align="center" valign="top">39.4 ± 0.9</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3183</td>
<td align="center" valign="top">FLLNKEMYL</td>
<td align="center" valign="top">12.9 ± 6.8</td>
<td align="center" valign="top">pp1a-3403</td>
<td align="center" valign="top">FLNGSCGSV</td>
<td align="center" valign="top">18.7 ± 3.2</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3467</td>
<td align="center" valign="top">VLAWLYAAV</td>
<td align="center" valign="top">45.0 ± 10.8</td>
<td align="center" valign="top">pp1a-3475</td>
<td align="center" valign="top">VINGDRWFL</td>
<td align="center" valign="top">85.0 ± 5.4</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3482</td>
<td align="center" valign="top">FLNRFTTTL</td>
<td align="center" valign="top">79.0 ± 9.6</td>
<td align="center" valign="top">pp1a-3583</td>
<td align="center" valign="top">LLLTILTSL</td>
<td align="center" valign="top">63.8 ± 3.1</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3639</td>
<td align="center" valign="top">FLLPSLATV</td>
<td align="center" valign="top">15.0 ± 4.4</td>
<td align="center" valign="top">pp1a-3662</td>
<td align="center" valign="top">RIMTWLDMV</td>
<td align="center" valign="top">76.5 ± 7.1</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3753</td>
<td align="center" valign="top">FLARGIVFM</td>
<td align="center" valign="top">71.2 ± 12.9</td>
<td align="center" valign="top">pp1a-3798</td>
<td align="center" valign="top">CLLNRYFRL</td>
<td align="center" valign="top">81.6 ± 20.2</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3807</td>
<td align="center" valign="top">TLGVYDYLV</td>
<td align="center" valign="top">61.7 ± 8.7</td>
<td align="center" valign="top">pp1a-3871</td>
<td align="center" valign="top">VLLSVLQQL</td>
<td align="center" valign="top">44.9 ± 6.0</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3886</td>
<td align="center" valign="top">KLWAQCVQL</td>
<td align="center" valign="top">27.2 ± 9.4</td>
<td align="center" valign="top">pp1a-4183</td>
<td align="center" valign="top">ALLSDLQDL</td>
<td align="center" valign="top">42.4 ± 6.1</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-4266</td>
<td align="center" valign="top">VLSFCAFAV</td>
<td align="center" valign="top">20.1 ± 6.1</td>
<td align="center" valign="top">pp1a-4283</td>
<td align="center" valign="top">YLASGGQPI</td>
<td align="center" valign="top">39.8 ± 6.2</td>
</tr>
<tr style="border-top: solid thin">
<td align="center" valign="top" colspan="6">Low binders</td>
</tr>
<tr style="border-top: solid thin">
<td align="center" valign="top">Name</td>
<td align="center" valign="top">Sequence</td>
<td align="center" valign="top">BL<sub>50</sub>
</td>
<td align="center" valign="top">Name</td>
<td align="center" valign="top">Sequence</td>
<td align="center" valign="top">BL<sub>50</sub>
</td>
</tr>
<tr style="border-top: solid thin">
<td align="center" valign="top">pp1a-572</td>
<td align="center" valign="top">GISQYSLRL</td>
<td align="center" valign="top">ND</td>
<td align="center" valign="top">pp1a-589</td>
<td align="center" valign="top">DLATNNLVV</td>
<td align="center" valign="top">ND</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-692</td>
<td align="center" valign="top">SIIIGGAKL</td>
<td align="center" valign="top">ND</td>
<td align="center" valign="top">pp1a-881</td>
<td align="center" valign="top">KTLQPVSEL</td>
<td align="center" valign="top">161.7 ± 28.3</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-1143</td>
<td align="center" valign="top">VLLAPLLSA</td>
<td align="center" valign="top">ND</td>
<td align="center" valign="top">pp1a-1148</td>
<td align="center" valign="top">LLSAGIFGA</td>
<td align="center" valign="top">ND</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-1214</td>
<td align="center" valign="top">FITESKPSV</td>
<td align="center" valign="top">122.1 ± 31.7</td>
<td align="center" valign="top">pp1a-1367</td>
<td align="center" valign="top">ILGTVSWNL</td>
<td align="center" valign="top">123.2 ± 11.3</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-1387</td>
<td align="center" valign="top">KLMPVCVET</td>
<td align="center" valign="top">174.2 ± 33.5</td>
<td align="center" valign="top">pp1a-1433</td>
<td align="center" valign="top">SLINTLNDL</td>
<td align="center" valign="top">123.4 ± 11.0</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-1642</td>
<td align="center" valign="top">FLGRYMSAL</td>
<td align="center" valign="top">124.1 ± 1.9</td>
<td align="center" valign="top">pp1a-1962</td>
<td align="center" valign="top">DLNGDVVAI</td>
<td align="center" valign="top">ND</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2076</td>
<td align="center" valign="top">ILKPANNSL</td>
<td align="center" valign="top">ND</td>
<td align="center" valign="top">pp1a-2226</td>
<td align="center" valign="top">LINIIIWFL</td>
<td align="center" valign="top">ND</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2228</td>
<td align="center" valign="top">NIIIWFLLL</td>
<td align="center" valign="top">ND</td>
<td align="center" valign="top">pp1a-2230</td>
<td align="center" valign="top">IIWFLLLSV</td>
<td align="center" valign="top">176.7 ± 6.3</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2235</td>
<td align="center" valign="top">LLSVCLGSL</td>
<td align="center" valign="top">ND</td>
<td align="center" valign="top">pp1a-2242</td>
<td align="center" valign="top">SLIYSTAAL</td>
<td align="center" valign="top">134.0 ± 7.6</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2249</td>
<td align="center" valign="top">ALGVLMSNL</td>
<td align="center" valign="top">ND</td>
<td align="center" valign="top">pp1a-2348</td>
<td align="center" valign="top">QLFFSYFAV</td>
<td align="center" valign="top">146.4 ± 19.7</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2363</td>
<td align="center" valign="top">WLMWLIINL</td>
<td align="center" valign="top">102.7 ± 6.4</td>
<td align="center" valign="top">pp1a-2364</td>
<td align="center" valign="top">LMWLIINLV</td>
<td align="center" valign="top">159.0 ± 42.8</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-2901</td>
<td align="center" valign="top">KLIEYTDFA</td>
<td align="center" valign="top">126.0 ± 2.5</td>
<td align="center" valign="top">pp1a-3344</td>
<td align="center" valign="top">SMQNCVLKL</td>
<td align="center" valign="top">104.5 ± 2.2</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3827</td>
<td align="center" valign="top">GLLPPKNSI</td>
<td align="center" valign="top">ND</td>
<td align="center" valign="top">pp1a-3839</td>
<td align="center" valign="top">KLNIKLLGV</td>
<td align="center" valign="top">213.5 ± 85.7</td>
</tr>
<tr>
<td align="center" valign="top">pp1a-3917</td>
<td align="center" valign="top">VLLSMQGAV</td>
<td align="center" valign="top">112.3 ± 7.2</td>
<td align="center" valign="top">pp1a-4032</td>
<td align="center" valign="top">MLFTMLRKL</td>
<td align="center" valign="top">165.8 ± 21.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<p id="P33">Data of peptide binding assays are shown as BL<sub>50</sub>, indicating a concentration (μM) of each peptide that yields the 50% relative binding as shown in the <xref ref-type="sec" rid="S8">materials and methods</xref>. Experiments were performed in triplicate and repeated twice with similar results. Data are given as mean values ± SD. High binders: BL<sub>50</sub> &lt; 10 μM; Medium binders: 10 μM ≤ BL<sub>50</sub> &lt; 100 μM; Low binders: BL<sub>50</sub> ≥ 100 μM or ND (not detected).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>Comparison of amino acid sequences of SARS-CoV-2 pp1a CTL epitopes with the amino acid sequence of SARS-CoV</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup>
<col span="3"/>
</colgroup>
<thead>
<tr>
<th align="center" valign="top" colspan="4">SARS-CoV-2</th>
<th align="center" valign="top" colspan="2">SARS-CoV</th>
</tr>
<tr style="border-top: solid thin">
<th align="left" valign="top">Name</th>
<th align="left" valign="top">Start-End</th>
<th align="left" valign="top">Sequence</th>
<th align="center" valign="top">Protein</th>
<th align="left" valign="top">Sequence</th>
<th align="center" valign="top">Identity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">pp1a-38</td>
<td align="left" valign="top">38-46</td>
<td align="left" valign="top">VLSEARQHL</td>
<td align="center" valign="top">nsp1</td>
<td align="left" valign="top">ALSEAREHL</td>
<td align="center" valign="top">89</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-52</td>
<td align="left" valign="top">52-60</td>
<td align="left" valign="top">GLVEVEKGV</td>
<td align="center" valign="top">nsp1</td>
<td align="left" valign="top">GLVELEKGV</td>
<td align="center" valign="top">89</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-84</td>
<td align="left" valign="top">84-92</td>
<td align="left" valign="top">VMVELVAEL</td>
<td align="center" valign="top">nsp1</td>
<td align="left" valign="top">KVVELVAEM</td>
<td align="center" valign="top">67</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-103</td>
<td align="left" valign="top">103-11</td>
<td align="left" valign="top">TLGVLVPHV</td>
<td align="center" valign="top">nsp1</td>
<td align="left" valign="top">TLGVLVPHV</td>
<td align="center" valign="top">100</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-445</td>
<td align="left" valign="top">445-53</td>
<td align="left" valign="top">GLNDNLLEI</td>
<td align="center" valign="top">nsp2</td>
<td align="left" valign="top">TLNEDLLEI</td>
<td align="center" valign="top">67</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-597</td>
<td align="left" valign="top">597-605</td>
<td align="left" valign="top">VMAYITGGV</td>
<td align="center" valign="top">nsp2</td>
<td align="left" valign="top">IMAYVTGGL</td>
<td align="center" valign="top">67</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-641</td>
<td align="left" valign="top">641-9</td>
<td align="left" valign="top">FLRDGWEIV</td>
<td align="center" valign="top">nsp2</td>
<td align="left" valign="top">FLKDAWEIL</td>
<td align="center" valign="top">67</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-1675</td>
<td align="left" valign="top">1675-83</td>
<td align="left" valign="top">YLATALLTL</td>
<td align="center" valign="top">nsp3</td>
<td align="left" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">pp1a-2785</td>
<td align="left" valign="top">2785-93</td>
<td align="left" valign="top">AIFYLITPV</td>
<td align="center" valign="top">nsp4</td>
<td align="left" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">pp1a-2884</td>
<td align="left" valign="top">2884-92</td>
<td align="left" valign="top">FLPRVFSAV</td>
<td align="center" valign="top">nsp4</td>
<td align="left" valign="top">FLPRVFSAV</td>
<td align="center" valign="top">100</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-3083</td>
<td align="left" valign="top">3083-91</td>
<td align="left" valign="top">LLFLMSFTV</td>
<td align="center" valign="top">nsp4</td>
<td align="left" valign="top">LLFLMSFTI</td>
<td align="center" valign="top">89</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-3403</td>
<td align="left" valign="top">3403-11</td>
<td align="left" valign="top">FLNGSCGSV</td>
<td align="center" valign="top">nsp5</td>
<td align="left" valign="top">FLNGSCGSV</td>
<td align="center" valign="top">100</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-3467</td>
<td align="left" valign="top">3467-75</td>
<td align="left" valign="top">VLAWLYAAV</td>
<td align="center" valign="top">nsp5</td>
<td align="left" valign="top">VLAWLYAAV</td>
<td align="center" valign="top">100</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-3583</td>
<td align="left" valign="top">3583-91</td>
<td align="left" valign="top">LLLTILTSL</td>
<td align="center" valign="top">nsp6</td>
<td align="left" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">pp1a-3662</td>
<td align="left" valign="top">3662-70</td>
<td align="left" valign="top">RIMTWLDMV</td>
<td align="center" valign="top">nsp6</td>
<td align="left" valign="top">RIMTWLELA</td>
<td align="center" valign="top">67</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-3710</td>
<td align="left" valign="top">3710-8</td>
<td align="left" valign="top">TLMNVLTLV</td>
<td align="center" valign="top">nsp6</td>
<td align="left" valign="top">TLMNVITLV</td>
<td align="center" valign="top">89</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-3732</td>
<td align="left" valign="top">3732-40</td>
<td align="left" valign="top">SMWALIISV</td>
<td align="center" valign="top">nsp6</td>
<td align="left" valign="top">SMWALVISV</td>
<td align="center" valign="top">89</td>
</tr>
<tr>
<td align="left" valign="top">pp1a-3886</td>
<td align="left" valign="top">3886-94</td>
<td align="left" valign="top">KLWAQCVQL</td>
<td align="center" valign="top">nsp7</td>
<td align="left" valign="top"/>
<td align="center" valign="top"/>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
